Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma.
Gupta A. et al, (2020), Br J Cancer, 122, 506 - 516
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019.
Garbe C. et al, (2020), Eur J Cancer, 126, 159 - 177
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019.
Garbe C. et al, (2020), Eur J Cancer, 126, 141 - 158
Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma.
Fairfax BP. et al, (2020), Nat Med, 26, 193 - 199
The quiescent fraction of chronic myeloid leukemic stem cells depends on BMPR1B, Stat3 and BMP4-niche signals to persist in patients in remission.
Jeanpierre S. et al, (2020), Haematologica, 106, 111 - 122
An ontogenetic switch drives the positive and negative selection of B cells
CORNALL R. et al, (2020), PNAS
Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement
Blagden SP. et al, (2020), British Journal of Cancer
Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: A UK consensus statement.
Peach H. et al, (2020), J Plast Reconstr Aesthet Surg, 73, 36 - 42
Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity.
Goswami P. et al, (2020), Front Pharmacol, 11
Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study.
Goswami P. et al, (2020), Front Pharmacol, 11
Immune checkpoint inhibitor-related colitis assessment and prognosis: can inflammatory bowel disease scoring point the way?
Cheung VTF. et al, (2020), JOURNAL OF CROHNS & COLITIS, 14, S286 - S288
Quality-of-life issues and symptoms reported by patients living with haematological malignancy: a qualitative study.
Goswami P. et al, (2020), Ther Adv Hematol, 11
Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO.
Goswami P. et al, (2020), Front Pharmacol, 11
Technological advances and computational approaches for alternative splicing analysis in single cells.
Wen WX. et al, (2020), Comput Struct Biotechnol J, 18, 332 - 343
Window of opportunity clinical trial designs to study cancer metabolism.
Aroldi F. and Lord SR., (2020), Br J Cancer, 122, 45 - 51
Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial
Sharma P. et al, (2019), Journal of Clinical Oncology, 37, 3484 - 3492
Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin.
Lord SR. et al, (2019), British journal of cancer
DEBIOC: A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophago-gastric adenocarcinoma
Thomas A. et al, (2019), European Journal of Cancer